Journal of Innovative Clinical Trials and Case Reports

Abstract

Background: Polyendocrine Metabolic Ovarian Syndrome (PMOS) is recognized as the most prevalent endocrine disorder among women of reproductive age, with an estimated prevalence of approximately 18% according to current Rotterdam diagnostic criteria. Conditions such as dyslipidemia, insulin resistance, hyperandrogenism, central adiposity, and chronic inflammation are frequently observed in women diagnosed with PMOS. These conditions predispose such individuals to an increased risk of developing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which is the most prevalent chronic liver disease worldwide, affecting approximately 25% of the global population. PMOS and MASLD represent two interconnected metabolic disorders that share overlapping risk factors

Objective: To determine the prevalence of MASLD in women with PCOS and correlate it with PCOS phenotypes.

Methods: This cross-sectional observational study was conducted in the Department of Obstetrics and Gynaecology, Jawaharlal Nehru Medical College, Aligarh Muslim University (A.M.U.), after obtaining approval from the Institutional Ethics Committee. A total of 50 women aged 18–40 years diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam 2003 criteria were consecutively enrolled after obtaining written informed consent

Results: MASLD prevalence significantly higher in PCOS (32%) vs controls (4%), p<0.001 . Phenotype A (HA+OD+PCOM) was the most common (72%) hyperandrogenic phenotypes (A, B, C) show the highest fatty liver rates

Conclusions: MASLD prevalence significantly higher in PCOS as compared to non PMOS